Loading market data...
Latest Top News
Shilpa Medicare Launches Bortezomib Injection in U.S., Enhancing Oncology Portfolio
Shilpa Medicare Ltd., a major oncology and critical care medicines company, has declared the launch of its NDA-approved Bortezomib for Injection (3.5mg/1.4ml) in the United States. This is an important achievement for the company as it extends its reach in the U.S. market with one of its critical...
Stay Ahead – Explore Now! Harmanpreet Kaur Deflects Handshake Query Ahead of Pakistan Clash






